Daliresp and Infusion site extravasation - a phase IV clinical study of FDA data

Summary:

Infusion site extravasation is reported as a side effect among people who take Daliresp (roflumilast), especially for people who are female, 60+ old, also take Spiriva, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Infusion site extravasation when taking Daliresp. It is created by eHealthMe based on reports of 4,674 people who have side effects when taking Daliresp from the FDA, and is updated regularly.

What is Daliresp?

Daliresp has active ingredients of roflumilast. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 4,722 Daliresp users. Check the latest studies of Daliresp.

What is Infusion site extravasation?

Infusion site extravasation (flow of (blood or lymph) from infusion site) is found to be associated with 645 drugs and 590 conditions by eHealthMe. Check the latest studies of Infusion site extravasation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

4,674 people reported to have side effects when taking Daliresp.
Among them, 21 people (0.45%) have Infusion site extravasation.

Could Daliresp cause Infusion site extravasation?

Among these 21 people:

What is the gender of people who have Infusion site extravasation when taking Daliresp? *

female: 90.48 %
male: 9.52 %

What is the age of people who have Infusion site extravasation when taking Daliresp? *

What are other drugs people take besides Daliresp? *

What are other side effects people have besides Infusion site extravasation? *

Infusion Site Pain: 16 people, 76.19%
Pneumonia: 14 people, 66.67%
Infusion Site Swelling: 12 people, 57.14%
Fatigue (feeling of tiredness): 10 people, 47.62%
White Blood Cell Count Increased: 8 people, 38.10%
Pulmonary Vascular Disorder: 8 people, 38.10%
Drug Level Decreased: 8 people, 38.10%
Dyspnea (difficult or laboured breathing): 8 people, 38.10%
Eye Pruritus (eye itching): 8 people, 38.10%
Infection: 8 people, 38.10%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 19 people, 90.48%
Primary Immunodeficiency Syndrome: 3 people, 14.29%
Pneumonia: 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Daliresp and have Infusion site extravasation?

- Check whether Infusion site extravasation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Daliresp:

Daliresp (4,722 reports)

Browse all side effects of Daliresp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site extravasation:

Infusion site extravasation (645 drugs)

Browse all the conditions that are associated with Infusion site extravasation:

Infusion site extravasation (590 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on roflumilast (the active ingredients of Daliresp) and Daliresp (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.